2,000
Views
13
CrossRef citations to date
0
Altmetric
Original Research

Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models

, , ORCID Icon, ORCID Icon, , , ORCID Icon, , , & show all
Article: e1445457 | Received 11 Jan 2018, Accepted 20 Feb 2018, Published online: 26 Mar 2018

References

  • Callahan MK. Immune Checkpoint Therapy in Melanoma. Cancer J. 2016;22(2):73–80. doi:10.1097/PPO.0000000000000183. PMID:27111901.
  • Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030. PMID:26027431.
  • Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016;34(8):871–8. doi:10.1200/JCO.2015.62.9345. PMID:26811525.
  • O'Donnell JS, Long GV, Scolyer RA, Teng MWL, Smyth MJ. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017;52:71–81. doi:10.1016/j.ctrv.2016.11.007. PMID:27951441.
  • Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B, Mueller B, Quaratino S, Sabatos-Peyton C, Petruzzelli L, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286–301. doi:10.1038/nrc.2017.17. PMID:28338065.
  • Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol. 2017;45:43–51. doi:10.1016/j.coi.2017.01.002.
  • Desrichard A, Snyder A, Chan TA. Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016;22(4):807–12. doi:10.1158/1078-0432.CCR-14-3175. PMID:26515495.
  • Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13(3):143–58. doi:10.1038/nrclinonc.2015.209. PMID:26598942.
  • de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, et al. Dendritic cell vaccination for metastatic melanoma. Melanoma Res. 2017;27(4):351–7. doi:10.1097/CMR.0000000000000356. PMID:28654547.
  • Cafri G, Sharbi-Yunger A, Tzehoval E, Alteber Z, Gross T, Vadai E, Margalit A, Gross G, Eisenbach L. mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity. Mol Ther. 2015;23(8):1391–400. doi:10.1038/mt.2015.90. PMID:25997427.
  • Sharbi-Yunger A, Grees M, Tzehoval E, Utikal J, Umansky V, Eisenbach L. mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. Oncoimmunology. 2016;5(6):e1160183. doi:10.1080/2162402X.2016.1160183. PMID:27471629.
  • Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med. 2017;9(2):137–53. doi:10.15252/emmm.201606857. PMID:28028012.
  • Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE, You MJ, DePinho RA, McMahon M, Bosenberg M. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet. 2009;41:544–52. doi:10.1038/ng.356. PMID:19282848.
  • Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. Transgenic mouse model for skin malignant melanoma. Oncogene. 1998;17(14):1885–8. doi:10.1038/sj.onc.1202077. PMID:9778055.
  • Meyer C, Sevko A, Ramacher M, Bazhin AV, Falk CS, Osen W, Borrello I, Kato M, Schadendorf D, Baniyash M, et al. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc Natl Acad Sci U S A. 2011;108(41):17111–6. doi:10.1073/pnas.1108121108. PMID:21969559.
  • Sevko A, Michels T, Vrohlings M, Umansky L, Beckhove P, Kato M, Shurin G V, Shurin MR, Umansky V. Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol. 2013;190(5):2464–71. doi:10.4049/jimmunol.1202781. PMID:23359505.
  • Dougan SK, Dougan M, Kim J, Turner JA, Ogata S, Cho H-I, Jaenisch R, Celis E, Ploegh HL. Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity. Cancer Immunol Res. 2013;1(2):99–111. doi:10.1158/2326-6066.CIR-13-0047. PMID:24459675.
  • Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI : database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3–4):213–9. doi:10.1007/s002510050595. PMID:10602881.
  • Cafri G, Amram E, Rinott G, Koifman G, Fishman S, Keisari Y, Tzehoval E, Margalit A, Eisenbach L, Gross G. Coupling presentation of MHC class I peptides to constitutive activation of antigen-presenting cells through the product of a single gene. Int Immunol. 2011;23(7):453–61. doi:10.1093/intimm/dxr033. PMID:21652516.
  • Fujiwara Y, Okada K, Omori T, Sugimura K, Miyata H, Ohue M, Kobayashi S, Takahashi H, Nakano H, Mochizuki C, et al. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50(5):1655–62. doi:10.3892/ijo.2017.3955. PMID:28393243.
  • Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991. PMID:28678778.
  • Cho H-I, Celis E. Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res. 2009;69(23):9012–9. doi:10.1158/0008-5472.CAN-09-2019. PMID:19903852.
  • Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res. 2017;5(1):3–8. doi:10.1158/2326-6066.CIR-16-0297. PMID:28052991.
  • Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94(1):41–53. doi:10.1189/jlb.1212631. PMID:23667165.
  • Mellman I. Dendritic cells: master regulators of the immune response. Cancer Immunol Res. 2013;1(3):145–9. doi:10.1158/2326-6066.CIR-13-0102. PMID:24777676.
  • Bender C, Hassel JC, Enk A. Immunotherapy of Melanoma. Oncol Res Treat. 2016;39(6):369–76. doi:10.1159/000446716. PMID:27259558.
  • Garg AD, Vara Perez M, Schaaf M, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology. 2017;6(7):e1328341. doi:10.1080/2162402X.2017.1328341. PMID:28811970.
  • Fridman WH, Zitvogel L, Sautès–Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–34. doi:10.1038/nrclinonc.2017.101. PMID:28741618.
  • Wilgenhof S, Corthals J, Van Nuffel AMT, Benteyn D, Heirman C, Bonehill A, Thielemans K, Neyns B. Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunol Immunother. 2015;64(3):381–8. doi:10.1007/s00262-014-1642-8. PMID:25548092.
  • Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN. Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev. 2015;67(4):731–53. doi:10.1124/pr.114.009456. PMID:26240218.
  • Kramps T, Probst J. Messenger RNA-based vaccines: progress, challenges, applications. Wiley Interdiscip Rev RNA. 2013;4(6):737–49. doi:10.1002/wrna.1189. PMID:23893949.
  • Eisenächer K, Steinberg C, Reindl W, Krug A. The role of viral nucleic acid recognition in dendritic cells for innate and adaptive antiviral immunity. Immunobiology. 2007;212(9–10):701–14. doi:10.1016/j.imbio.2007.09.007. PMID:18086372.
  • Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, Pen J, Bonehill A, Heirman C, Breckpot K, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res. 2012;72(7):1661–71. doi:10.1158/0008-5472.CAN-11-2957. PMID:22337996.
  • Wilgenhof S, Van Nuffel AMT, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol. 2013;24(10):2686–93. doi:10.1093/annonc/mdt245. PMID:23904461.
  • Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515:572–6. doi:10.1038/nature14001. PMID:25428506.
  • Marabelle A, Tselikas L, de Baere T, Houot R. Intratumoral immunotherapy: using the tumor as the remedy. Ann Oncol. 2017;28(suppl_12):xii33−43. doi:10.1093/annonc/mdx683. PMID:29253115.
  • Overwijk WW. Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Curr Opin Immunol. 2017;47:103–9. doi:10.1016/j.coi.2017.07.015. PMID:28806603.
  • Kumai T, Kobayashi H, Harabuchi Y, Celis E. Peptide vaccines in cancer-old concept revisited. Curr Opin Immunol. 2017;45:1–7. doi:10.1016/j.coi.2016.11.001. PMID:27940327.
  • van Stipdonk MJB, Hardenberg G, Bijker MS, Lemmens EE, Droin NM, Green DR, Schoenberger SP. Dynamic programming of CD8+ T lymphocyte responses. Nat Immunol. 2003;4(4):361–5. doi:10.1038/ni912. PMID:12640451.
  • Kannengiesser C, Spatz A, Michiels S, Eychène A, Dessen P, Lazar V, Winnepenninckx V, Lesueur F, Druillennec S, Robert C, et al. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol. 2008;1(4):425–30. doi:10.1016/j.molonc.2008.01.002. PMID:19383316.
  • Polkowska M, Czepielewska E, Kozłowska-Wojciechowska M. Drug Combinations as the New Standard for Melanoma Treatment. Curr Treat Options Oncol. 2016;17(12):61. doi:10.1007/s11864-016-0436-y. PMID:27766547.
  • Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, Van der Jeught K, Arce F, Guerrero-Setas D, Fernandez-Irigoyen J, et al. A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. Oncotarget. 2014;5(17):7843–57. doi:10.18632/oncotarget.2279. PMID:25151659.
  • Wu X, Feng QM, Wang Y, Shi J, Ge HL, Di W. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy. Cancer Immunol Immunother. 2010;59(2):279–91. doi:10.1007/s00262-009-0749-9. PMID:19727719.
  • Sevko A, Kremer V, Falk C, Umansky L, Shurin MR, Shurin G V, Umansky V. Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol. 2012;9(3):275–81. doi:10.3109/1547691X.2012.655343. PMID:22449053.
  • Gonda K, Shibata M, Ohtake T, Matsumoto Y, Tachibana K, Abe N, Ohto H, Sakurai K, Takenoshita S. Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett. 2017;14(2):1766–74. doi:10.3892/ol.2017.6305. PMID:28789407.
  • Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136(10):2352–60. doi:10.1002/ijc.29297. PMID:25353097.
  • Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, et al. Induction of resident memory T cells enhances the efficacy of cancer vaccine. Nat Commun. 2017;8:15221. doi:10.1038/ncomms15221. PMID:28537262.
  • van Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber W-J, Ossendorp F, Melief CJ, Arens R. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol. 2012;189(7):3397–403. doi:10.4049/jimmunol.1201540. PMID:22914049.
  • Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med. 2015;7(283):283ra52. doi:10.1126/scitranslmed.aaa4306. PMID:25877890.
  • Ali OA, Lewin SA, Dranoff G, Mooney DJ. Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication. Cancer Immunol Res. 2016;4(2):95–100. doi:10.1158/2326-6066.CIR-14-0126. PMID:26669718.
  • Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J. PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol. 2009;21(9):1065–77. doi:10.1093/intimm/dxp072. PMID:19651643.
  • Liu CY, Wang YM, Wang CL, Feng PH, Ko HW, Liu YH, Wu YC, Chu Y, Chung F-T, Kuo CH, et al. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14−/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010;136(1):35–45. doi:10.1007/s00432-009-0634-0. PMID:19572148.
  • Lutz MB, Kukutsch N, Ogilvie AL, Roßner S, Koch F, Romani N, Schuler G, Rössner S. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223(1):77–92. doi:10.1016/S0022-1759(98)00204-X. PMID:10037236.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.